Pharmacy school

SIUE School of Pharmacy Ranks No. 1 Regionally and Top 25 in U.S.

Retrieved on: 
Tuesday, June 14, 2022
Faculty, Pharmacy school, SOP, Southern Illinois University, Curriculum, Research, Licensure, Pharmacist, Doctor of Pharmacy, MPJE, Southern Illinois University Edwardsville, School, Health, Student, Patient, NAPLEX, Drug design, Chronic pain, UCL School of Pharmacy, Education, Medicine, Pharmacy

EDWARDSVILLE, Ill., June 14, 2022 /PRNewswire-PRWeb/ -- Southern Illinois University Edwardsville's School of Pharmacy (SOP) graduates have again exceeded state and national first-attempt pass rates on licensure exams, extending the program's status as number one in Illinois and Missouri and among the top 25 in the country.

Key Points: 
  • The North American Pharmacist Licensure Exam (NAPLEX) and the Illinois Multistate Pharmacy Jurisprudence Examination (MPJE) are components of the licensing process for pharmacists in the United States.
  • The Class of 2021's first-attempt NAPLEX pass rate is 91%, compared to 84% national average and a state average of 75%.
  • Its first-attempt pass rate for the Illinois MPJE is 89%, outpacing the 80% national average and 73% state average.
  • Areas of excellence include a drug design and discovery core, pediatric practice, chronic pain research and practice, and diabetes research and practice.

API partners with the University of Waterloo scientists to develop broad-spectrum small molecule therapeutics against coronaviruses

Retrieved on: 
Tuesday, May 10, 2022
Drug development, School, Department, University, Assistant professor, Coronavirus, API, Organization, Therapy, Industry, Patent, Knowledge, Chemistry, Associate professor, COVID-19, Pharmacy school, University of Waterloo, Infection, CEO, Research, UCPH Department of Biology, AB, Fine chemical, Pharmaceutical industry, Pharmacy

The API team and investigators will work together to design and develop small molecule therapeutics to fight the current and the future variants of coronavirus.

Key Points: 
  • The API team and investigators will work together to design and develop small molecule therapeutics to fight the current and the future variants of coronavirus.
  • This team of research scientists and industry experts will work together in developing potent small molecule drugs that can effectively target a protease enzyme that is a critical viral replication machinery in coronaviruses.
  • We are optimistic about the success of our approach," said Professor Ganesan, School of Pharmacy, University of Waterloo.
  • With a network of over 100 pharmaceutical scientists, clinicians, regulatory, patent, and market experts, API brings life-saving research to the real world.

Pharma Pioneer & Longtime Patient Advocate Gail Trauco Receives Top 100 Women to KNOW in North America! Award

Retrieved on: 
Tuesday, April 19, 2022
Insurance, LGBTQ+, Clinical Trials, Professional Services, Other Health, Managed Care, Pharmaceutical, Consumer, Health, Oncology, KNOW, BSN, Annual, Government, LGBTQ, Woman, Compliance, Organization, Patient, Pharmacy school, Color, Candy, Multimedia, Industry, Medicine, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220419005133/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220419005133/en/
    The PharmaKon CEO/founder Gail Trauco (Photo: Business Wire)
    Recently tapped to receive the Top 100 Women to KNOW in North America!
  • Award , Trauco is an invaluable resource and inspired solution provider to patients, health care providers and pharmaceutical companies alike.
  • Trauco will receive her award at the Annual KNOW Summit on May 17, 2022 at the Saguaro Hotel in Scottsdale, Arizona.
  • For more information about Gail Trauco and The PharmaKon and its industry leading, decentralized clinical trials go to: www.ThePharmaKonLLC.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005133/en/

Innovative Therapy that "Tricks" and Destroys Cancer Cells Advances to Clinical Trial

Retrieved on: 
Friday, April 8, 2022
National, Glioblastoma, DRS, Leadership, III, Trial of the century, Clinical trial, Growth, Medical College of Wisconsin, Education, Markey Cancer Center, Division, Research, Pharmacy, Doctor of Philosophy, Faculty, School, Biometrics, Harvard University, Associate, LON, Cancer, History, MCW, CEO, Gam, Medical college, MD, Brain, LLC, Quality of life, Health, NIH, PACS, Froedtert Hospital, Physician, Student, OTCQB, Solution, IB, Stanford University, Iron, Pharmacy school, Hematology, Patient, Disease, Neurology, Medical imaging, Aluminium, Medicine, Central Wisconsin Film Festival, Biophysics

MILWAUKEE , April 8, 2022 /PRNewswire/ -- A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Center has led to a clinical trial for the treatment of glioblastoma, a rare and aggressive form of brain cancer, yet the most common primary brain tumor in adults.

Key Points: 
  • Now, a new clinical study open at Froedtert & the Medical College of Wisconsin will evaluate an alternative treatment that is administered orally.
  • Numerous studies examining the relationship between iron and cancer show that increased levels of iron in the body can be associated with increased cancer risk and severity, because cancer cells depend on iron to multiply and spread.
  • Because of gallium's similarity to Fe(III), it enters cancer cells instead of iron, preventing their multiplication.
  • The trial is being sponsored by Imaging Biometrics with supporting grants from the Musella Brain Tumor Foundation and the MCW Cancer Center.

Neuroscience Institute Formed to Further Research and Advancements in Treating Neurological Disorders

Retrieved on: 
Tuesday, January 11, 2022
Medicine, Research, Patient, NIH, Neurosurgery, Sanford, Mischer Neuroscience Institute, Education, Growth, Spine, Student, School, Health, Leadership, MCW, History, National, NSI, Faculty, Spinal cord, NRC, Disorder, Pharmacy school, Doctor of Philosophy, MD, Pharmacy, Medical College of Wisconsin, Neuroscience, Peripheral nervous system, Medical college, Professor, Brain, Partnership, Physician, Management, Child, Central Wisconsin Airport

In his new role, Dr. Kurpad will be responsible for the overall strategy, growth, and operation of the Neuroscience Institute (NSI) in collaboration with associated clinical departments and programs, the Neuroscience Research Center (NRC) and research enterprises.

Key Points: 
  • In his new role, Dr. Kurpad will be responsible for the overall strategy, growth, and operation of the Neuroscience Institute (NSI) in collaboration with associated clinical departments and programs, the Neuroscience Research Center (NRC) and research enterprises.
  • "Dr. Kurpad's vast experience and expertise across the field of neuroscience are invaluable in propelling the NSI mission forward."
  • This total includes highly competitive research and training awards from the National Institutes of Health (NIH).Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials.
  • Additionally, more than 1,650 physicians provide care in virtually every specialty of medicine for more than 2.8 million patients annually.

Fairleigh Dickinson U Names New Provost; Longtime faculty member and administrator to start as top academic officer in January 2022

Retrieved on: 
Monday, January 10, 2022
Wroxton Abbey, BS, Chemistry, Occupational therapy, Social work, FDU, Senior, Growth, Fairleigh Dickinson University, School, Department, Public health, Outline of health sciences, Strategic planning, Program, Alumnus, Pharmacy school, MA, Doctor of Philosophy, AACSB, Princeton University, Organization, University, Management, Medicine, Pharmacy

Avaltroni became the dean of FDU's School of Pharmacy as it was then called as it welcomed its first class in 2012.

Key Points: 
  • Avaltroni became the dean of FDU's School of Pharmacy as it was then called as it welcomed its first class in 2012.
  • Recently he led the creation of new programs in public health, physician assistant studies, occupational therapy, and social work.
  • "Fairleigh Dickinson University has been an integral part of my academic journey since my college experience," said Michael Avaltroni.
  • Fairleigh Dickinson University offers over 100 undergraduate and graduate degree programs, including doctoral programs in pharmacy, nursing practice, clinical psychology and school psychology; and an AACSB-accredited business school.

The PharmaKon Brings New Access, Diversity to Clinical Trials Through its Allied Approach to Meeting Patients Where They Are

Retrieved on: 
Wednesday, October 6, 2021
Professional Services, Nursing, Health, Venture Capital, Clinical Trials, Pharmaceutical, Clinical trial, Pharmakon (philosophy), Telehealth, EDC, Compliance, BSN, MTD, Health, Solution, Transport, Culture, FDA, Patient, Maxima and minima, Electronic data capture, University of California, San Francisco, Pharmacy, The Co Founder, Index (publishing), Connected health, Semen, Urine, Saliva, University, Woman, CWI, Female, Awareness, Doctorate, Pharmacy school, Colorado EKG Repository, LGBTQ, Pharmakon—Danish College of Pharmacy Practice, Color, Safety, Organization, Fortune 1000, Nursing, ALP, Government, Industry, Pharmaceutical industry, Medicine

Three nursing specialties are being used by The PharmaKon to staff its clinical trials: virtual nurses, remote mobile nurses, and patient concierges.

Key Points: 
  • Three nursing specialties are being used by The PharmaKon to staff its clinical trials: virtual nurses, remote mobile nurses, and patient concierges.
  • Over the last two decades few changes have been made to ensure inclusion and diversity in clinical trials, adds Curtis Wilson, VP Clinical Operations at The PharmaKon.
  • Clinical trials are now available to patients who otherwise would not be able to participate in studies.
  • Rural and marginalized communities, LGBTQ, people of color and low-income patients now have an equal opportunity to take part in innovative clinical trials.

California Pharmacists Association Announces New President, Names 2021-2022 Board of Trustees

Retrieved on: 
Thursday, September 16, 2021
General Health, Other Health, Hospitals, Health, Pharmaceutical, Low-residency program, School, Association, USC, Clinical pharmacy, University, Pharmacist, Trustee, Health, Pharmacy school, Doctor of Pharmacy, Pharmacy technician, USC School of Pharmacy, COVID-19, APH, Daily Journal Corporation, Leadership

The California Pharmacists Association (CPhA) announced today that Richard H. Dang, PharmD, APh, BCACP, FCPhA, was installed as President of the association on September 11, 2021 at the CPhA House of Delegates annual business meeting held in Sacramento, California.

Key Points: 
  • The California Pharmacists Association (CPhA) announced today that Richard H. Dang, PharmD, APh, BCACP, FCPhA, was installed as President of the association on September 11, 2021 at the CPhA House of Delegates annual business meeting held in Sacramento, California.
  • Currently, Dr. Dang is an Assistant Professor of Clinical Pharmacy and the Residency Program Director at the University of Southern California (USC), School of Pharmacy.
  • He serves as Chair of the CPhA COVID-19 Taskforce and as a member of the California State COVID-19 Testing Taskforce.
  • Joining Dr. Dang on the CPhA Board of Trustees are the following officers and trustees who were installed into their respective offices during the ceremony:
    The California Pharmacists Association (CPhA) is the largest statewide professional association for pharmacists, student pharmacists and pharmacy technicians in the country.

Locate Bio Closes £10 Million Funding Round

Retrieved on: 
Friday, September 3, 2021
Medical Devices, Health, Surgery, Clinical Trials, General Health, Biotechnology, Patient, Acquisition, University of Medicine and Health Sciences, University, Osteomyelitis, Regeneration, Surgeon, Royal College of Surgeons, School, Pharmacy school, Outline of health sciences, Company, Degenerative disc disease, BGF, Infection, COO, Technology, Bio, CEO, Royal college, RCSI, Growth, Food, Regenerative medicine, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry

Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that it has raised an oversubscribed 10 million of equity investment in a funding round co-led by existing shareholder Mercia Asset Management and new investor BGF.

Key Points: 
  • Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that it has raised an oversubscribed 10 million of equity investment in a funding round co-led by existing shareholder Mercia Asset Management and new investor BGF.
  • The investment brings the total funds raised by Locate Bio to over 18 million.
  • In September 2020, Locate Bio in-licensed multiple late-stage orthobiologics assets from the Royal College of Surgeons in Irelands (RCSI) University of Medicine and Health Sciences.
  • John von Benecke, CEO of Locate Bio, said: This investment round is truly transformational for Locate Bio and I would like to thank Mercia for their continued support and collaboration and to welcome BGF.

Sweet Earth Provides Update on Bioavailability Research

Retrieved on: 
Wednesday, August 4, 2021
Navy Office of Community Outreach, Permeation

VANCOUVER, BC, Aug. 4, 2021 /PRNewswire/ -Sweet Earth Holdings Corp. (CSE: SE)(FSE: 1KZ1) (OTCQB: SEHCF)("Sweet Earth" the "Company") is pleased to provide an update on its ongoing product research that is being conducted with NAVCO Pharmaceuticals Limited ("Navco"), an accredited laboratory located in Burlington, Ontario.

Key Points: 
  • VANCOUVER, BC, Aug. 4, 2021 /PRNewswire/ -Sweet Earth Holdings Corp. (CSE: SE)(FSE: 1KZ1) (OTCQB: SEHCF)("Sweet Earth" the "Company") is pleased to provide an update on its ongoing product research that is being conducted with NAVCO Pharmaceuticals Limited ("Navco"), an accredited laboratory located in Burlington, Ontario.
  • The current study involves in vitro skin permeation research to measure the performance of Sweet Earth Cream in the semisolid formulation.
  • The Sweet Earth / NAVCO study created an hour-by-hour study to measure the effectiveness over a six-hour period.
  • Peter Espig, CEO of Sweet Earth, commented, "We have always based product development on science, not by simply combining ingredients.